DeVita V T
Important Adv Oncol. 1991:241-54.
Responsibly handled, a mechanism such as a Clinical Alert can provide physicians with enough information to deal with the early release of data to the public. The journal peer review system was established primarily as an academic tool to allow publication of scientific work for the purpose of communicating information among scientists and physicians. Since both the number of papers published by an investigator and the quality of the journal publishing them are important to academic advancement, bypassing this system naturally threatens many physicians and scientists. The Clinical Alert, however, served its purpose and was well received by the majority of practicing physicians and the public. In fact, a second Alert was issued by NCI in October 1989 when data became available on the effectiveness of a new adjuvant drug therapy for a common stage of colon cancer (Appendix B) and, at a workshop convened by the National Cancer Advisory Board, where the mechanism of the Clinical Alerts was discussed, it was apparent that most participants felt that maintaining this process was important. In light of the current revolution in biology, the public's interest in receiving the benefits of its financial support of the national research enterprise, and access by the press to both scientific literature and meetings, it seems appropriate for public officials, especially when mandated by Congress, to take the responsibility of releasing some types of data to the public before traditional peer review. Some visible public decision-making process must, however, be used where the pros and cons of early release of a particular data set can be discussed, as was done with the original NCI Clinical Alert.(ABSTRACT TRUNCATED AT 250 WORDS)
如果处理得当,像“临床警报”这样的机制可以为医生提供足够信息,以便应对向公众提前发布数据的情况。期刊同行评审系统最初是作为一种学术工具建立的,目的是发表科学著作,以便在科学家和医生之间交流信息。由于研究者发表的论文数量以及发表其论文的期刊质量对学术进步都很重要,绕过这一系统自然会威胁到许多医生和科学家。然而,“临床警报”达到了其目的,受到了大多数执业医生和公众的欢迎。事实上,1989年10月,当关于一种用于常见结肠癌阶段的新辅助药物治疗效果的数据可用时,美国国家癌症研究所发布了第二次警报。在国家癌症咨询委员会召开的一次研讨会上,讨论了“临床警报”机制,很明显,大多数与会者认为维持这一过程很重要。鉴于当前生物学领域的变革、公众对从其对国家研究事业的财政支持中受益的兴趣,以及媒体对科学文献和会议的获取,公职人员,尤其是在国会授权的情况下,在传统同行评审之前承担向公众发布某些类型数据的责任似乎是合适的。然而,必须采用某种明显的公共决策程序,以便能够讨论提前发布特定数据集的利弊,就像美国国家癌症研究所最初的“临床警报”那样。(摘要截选于250词)